SCHEMBL4658019

SCHEMBL4658019

O=c1ccc2cc(O)c(O)c(O)c2o1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 7/20 0.75
MGAM O43451 5/20 0.75
SI P14410 5/20 0.75
MGAM2 Q2M2H8 5/20 0.75
MCL1 Q07820 10/20 0.68
KDM4E B2RXH2 4/20 0.68
ALDH1A1 P00352 4/20 0.68
HPGD P15428 4/20 0.68
HSD17B10 Q99714 4/20 0.68
MAPT P10636 3/20 0.68
ALOX15 P16050 3/20 0.68
SMN1; SMN2 Q16637 3/20 0.68
TDP1 Q9NUW8 3/20 0.68
LMNA P02545 2/20 0.68
CYP1A2 P05177 2/20 0.68
CYP3A4 P08684 2/20 0.68
PRKD3 O94806 1/20 0.68
EGFR P00533 1/20 0.68
PRKCG P05129 1/20 0.68
PRKCB P05771 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Daphnetin SCHEMBL29612544 0.81 MCL1 (1.00) GAAMGAMSIMGAM2MCL1
Daphnetin SCHEMBL128212 0.81 MCL1 (1.00) GAAMGAMSIMGAM2MCL1
SCHEMBL15171956 0.80 MCL1 (0.58) GAAMGAMSIMGAM2MCL1
Daphnetin SCHEMBL27885599 0.79 MCL1 (0.96) GAAMGAMSIMGAM2MCL1
Daphnetin SCHEMBL29041019 0.79 MCL1 (0.96) GAAMGAMSIMGAM2MCL1
Fraxetin SCHEMBL43472 0.78 CA9 (1.00) GAAMGAMSIMGAM2MCL1
SCHEMBL4659463 0.78 CA9 (0.77) GAAMGAMSIMGAM2MCL1
Fraxetin SCHEMBL30010613 0.78 CA9 (1.00) GAAMGAMSIMGAM2MCL1
Daphnetin SCHEMBL28751158 0.78 MCL1 (0.92) GAAMGAMSIMGAM2MCL1
Daphnetin SCHEMBL28897878 0.78 MCL1 (0.92) GAAMGAMSIMGAM2MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110819665-B Preparation method of 6,7,8-trihydroxy coumarin 苏州大学 2023-02-24 CN claimed
CN-115433151-A Preparation method of 6,7,8-trihydroxy coumarin 苏州大学 2022-12-06 CN claimed
CN-111803492-A Application of coumarin compound in preparation of medicine for treating hepatitis B 苏州大学 2020-10-23 CN claimed
CN-110819665-A Preparation method of 6, 7, 8-trihydroxy coumarin 苏州大学 2020-02-21 CN claimed
CN-115869301-B Application of coumarin compound in preparation of medicine for treating hepatitis 苏州大学 2025-04-01 CN disclosed
CN-115869301-B Application of coumarin compound in preparation of medicine for treating hepatitis 苏州大学 2025-04-01 CN disclosed
CN-115869301-A Application of coumarin compound in preparing medicine for treating hepatitis 苏州大学 2023-03-31 CN disclosed
CN-115869301-A Application of coumarin compound in preparing medicine for treating hepatitis 苏州大学 2023-03-31 CN disclosed
CN-110819665-B Preparation method of 6,7,8-trihydroxy coumarin 苏州大学 2023-02-24 CN disclosed
CN-110819665-B Preparation method of 6,7,8-trihydroxy coumarin 苏州大学 2023-02-24 CN disclosed
CN-110819665-B Preparation method of 6,7,8-trihydroxy coumarin 苏州大学 2023-02-24 CN disclosed
CN-115433151-A Preparation method of 6,7,8-trihydroxy coumarin 苏州大学 2022-12-06 CN disclosed
EP-1763520-B1 USE OF TRISUBSTITUTED BENZOPYRANONES SCHWABE WILLMAR GMBH & CO (DE) 2008-12-17 EP disclosed
EP-1763520-B1 USE OF TRISUBSTITUTED BENZOPYRANONES SCHWABE WILLMAR GMBH & CO (DE) 2008-12-17 EP disclosed
US-20080020068-A1 Use Of Trisubstituted Benzopyranones DR.WILLMAR SCHWABE GMBH & CO. KG (DE) 2008-01-24 US disclosed
US-20080020068-A1 Use Of Trisubstituted Benzopyranones DR.WILLMAR SCHWABE GMBH & CO. KG (DE) 2008-01-24 US disclosed
US-20080020068-A1 Use Of Trisubstituted Benzopyranones DR.WILLMAR SCHWABE GMBH & CO. KG (DE) 2008-01-24 US disclosed
CN-101044132-A Use of trisubstituted benzopyranones SCHWABE WILLMAR GMBH & CO (DE) 2007-09-26 CN disclosed
EP-1763520-A2 USE OF TRISUBSTITUTED BENZOPYRANONES Dr. Willmar Schwabe GmbH & Co. KG (DE) 2007-03-21 EP disclosed
WO-2006002918-A2 USE OF TRISUBSTITUTED BENZOPYRANONES DR. WILLMAR SCHWABE GMBH & CO. KG (DE) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080020068-A1 Use Of Trisubstituted Benzopyranones PTGS1, PTGES, NFKBIA GAA 1094/4885MGAM 2089/4885SI 246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.